Literature DB >> 27669460

ChREBP regulates fructose-induced glucose production independently of insulin signaling.

Mi-Sung Kim, Sarah A Krawczyk, Ludivine Doridot, Alan J Fowler, Jennifer X Wang, Sunia A Trauger, Hye-Lim Noh, Hee Joon Kang, John K Meissen, Matthew Blatnik, Jason K Kim, Michelle Lai, Mark A Herman.   

Abstract

Obese, insulin-resistant states are characterized by a paradoxical pathogenic condition in which the liver appears to be selectively insulin resistant. Specifically, insulin fails to suppress glucose production, yet successfully stimulates de novo lipogenesis. The mechanisms underlying this dysregulation remain controversial. Here, we hypothesized that carbohydrate-responsive element-binding protein (ChREBP), a transcriptional activator of glycolytic and lipogenic genes, plays a central role in this paradox. Administration of fructose increased hepatic hexose-phosphate levels, activated ChREBP, and caused glucose intolerance, hyperinsulinemia, hypertriglyceridemia, and hepatic steatosis in mice. Activation of ChREBP was required for the increased expression of glycolytic and lipogenic genes as well as glucose-6-phosphatase (G6pc) that was associated with the effects of fructose administration. We found that fructose-induced G6PC activity is a major determinant of hepatic glucose production and reduces hepatic glucose-6-phosphate levels to complete a homeostatic loop. Moreover, fructose activated ChREBP and induced G6pc in the absence of Foxo1a, indicating that carbohydrate-induced activation of ChREBP and G6PC dominates over the suppressive effects of insulin to enhance glucose production. This ChREBP/G6PC signaling axis is conserved in humans. Together, these findings support a carbohydrate-mediated, ChREBP-driven mechanism that contributes to hepatic insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27669460      PMCID: PMC5096918          DOI: 10.1172/JCI81993

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  68 in total

1.  A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose 6-phosphate and fructose 1-phosphate.

Authors:  E Van Schaftingen
Journal:  Eur J Biochem       Date:  1989-01-15

2.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Authors:  Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

3.  Novel mechanism of positive versus negative regulation by thyroid hormone receptor β1 (TRβ1) identified by genome-wide profiling of binding sites in mouse liver.

Authors:  Preeti Ramadoss; Brian J Abraham; Linus Tsai; Yiming Zhou; Ricardo H Costa-e-Sousa; Felix Ye; Martin Bilban; Keji Zhao; Anthony N Hollenberg
Journal:  J Biol Chem       Date:  2013-11-27       Impact factor: 5.157

Review 4.  Short-term control of glucokinase activity: role of a regulatory protein.

Authors:  E Van Schaftingen; M Detheux; M Veiga da Cunha
Journal:  FASEB J       Date:  1994-04-01       Impact factor: 5.191

5.  Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets.

Authors:  Jean-Marc Schwarz; Peter Linfoot; Doris Dare; Karmen Aghajanian
Journal:  Am J Clin Nutr       Date:  2003-01       Impact factor: 7.045

6.  Glucose activates ChREBP by increasing its rate of nuclear entry and relieving repression of its transcriptional activity.

Authors:  Michael N Davies; Brennon L O'Callaghan; Howard C Towle
Journal:  J Biol Chem       Date:  2008-06-30       Impact factor: 5.157

7.  Hyperinsulinemic-euglycemic clamp to assess insulin sensitivity in vivo.

Authors:  Jason K Kim
Journal:  Methods Mol Biol       Date:  2009

Review 8.  Selective versus total insulin resistance: a pathogenic paradox.

Authors:  Michael S Brown; Joseph L Goldstein
Journal:  Cell Metab       Date:  2008-02       Impact factor: 27.287

9.  Fructose 2,6-bisphosphate is essential for glucose-regulated gene transcription of glucose-6-phosphatase and other ChREBP target genes in hepatocytes.

Authors:  Catherine Arden; Susan J Tudhope; John L Petrie; Ziad H Al-Oanzi; Kirsty S Cullen; Alex J Lange; Howard C Towle; Loranne Agius
Journal:  Biochem J       Date:  2012-04-01       Impact factor: 3.857

10.  Glucose-6-phosphate-mediated activation of liver glycogen synthase plays a key role in hepatic glycogen synthesis.

Authors:  Alexander von Wilamowitz-Moellendorff; Roger W Hunter; Mar García-Rocha; Li Kang; Iliana López-Soldado; Louise Lantier; Kashyap Patel; Mark W Peggie; Carlos Martínez-Pons; Martin Voss; Joaquim Calbó; Patricia T W Cohen; David H Wasserman; Joan J Guinovart; Kei Sakamoto
Journal:  Diabetes       Date:  2013-08-29       Impact factor: 9.461

View more
  75 in total

1.  HCF-1 Regulates De Novo Lipogenesis through a Nutrient-Sensitive Complex with ChREBP.

Authors:  Elizabeth A Lane; Dong Wook Choi; Luisa Garcia-Haro; Zebulon G Levine; Meghan Tedoldi; Suzanne Walker; Nika N Danial
Journal:  Mol Cell       Date:  2019-06-18       Impact factor: 17.970

2.  Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis.

Authors:  Pengcheng Bu; Kai-Yuan Chen; Kun Xiang; Christelle Johnson; Scott B Crown; Nikolai Rakhilin; Yiwei Ai; Lihua Wang; Rui Xi; Inna Astapova; Yan Han; Jiahe Li; Bradley B Barth; Min Lu; Ziyang Gao; Robert Mines; Liwen Zhang; Mark Herman; David Hsu; Guo-Fang Zhang; Xiling Shen
Journal:  Cell Metab       Date:  2018-04-26       Impact factor: 27.287

Review 3.  Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.

Authors:  Thomas Jensen; Manal F Abdelmalek; Shelby Sullivan; Kristen J Nadeau; Melanie Green; Carlos Roncal; Takahiko Nakagawa; Masanari Kuwabara; Yuka Sato; Duk-Hee Kang; Dean R Tolan; Laura G Sanchez-Lozada; Hugo R Rosen; Miguel A Lanaspa; Anna Mae Diehl; Richard J Johnson
Journal:  J Hepatol       Date:  2018-02-02       Impact factor: 25.083

Review 4.  Glucose transporters in the small intestine in health and disease.

Authors:  Hermann Koepsell
Journal:  Pflugers Arch       Date:  2020-08-23       Impact factor: 3.657

5.  Deletion of Fructokinase in the Liver or in the Intestine Reveals Differential Effects on Sugar-Induced Metabolic Dysfunction.

Authors:  Ana Andres-Hernando; David J Orlicky; Masanari Kuwabara; Takuji Ishimoto; Takahiko Nakagawa; Richard J Johnson; Miguel A Lanaspa
Journal:  Cell Metab       Date:  2020-06-04       Impact factor: 27.287

6.  Dietary Sugars Alter Hepatic Fatty Acid Oxidation via Transcriptional and Post-translational Modifications of Mitochondrial Proteins.

Authors:  Samir Softic; Jesse G Meyer; Guo-Xiao Wang; Manoj K Gupta; Thiago M Batista; Hans P M M Lauritzen; Shiho Fujisaka; Dolors Serra; Laura Herrero; Jennifer Willoughby; Kevin Fitzgerald; Olga Ilkayeva; Christopher B Newgard; Bradford W Gibson; Birgit Schilling; David E Cohen; C Ronald Kahn
Journal:  Cell Metab       Date:  2019-10-01       Impact factor: 27.287

7.  Delayed access to feed alters expression of genes associated with carbohydrate and amino acid utilization in newly hatched broiler chicks.

Authors:  Jason A Payne; Monika Proszkowiec-Weglarz; Laura E Ellestad
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-10-09       Impact factor: 3.619

Review 8.  Fructose and hepatic insulin resistance.

Authors:  Samir Softic; Kimber L Stanhope; Jeremie Boucher; Senad Divanovic; Miguel A Lanaspa; Richard J Johnson; C Ronald Kahn
Journal:  Crit Rev Clin Lab Sci       Date:  2020-01-14       Impact factor: 6.250

9.  MondoA drives muscle lipid accumulation and insulin resistance.

Authors:  Byungyong Ahn; Shibiao Wan; Natasha Jaiswal; Rick B Vega; Donald E Ayer; Paul M Titchenell; Xianlin Han; Kyoung Jae Won; Daniel P Kelly
Journal:  JCI Insight       Date:  2019-07-09

Review 10.  Regulation of Glucose Production in the Pathogenesis of Type 2 Diabetes.

Authors:  Ashot Sargsyan; Mark A Herman
Journal:  Curr Diab Rep       Date:  2019-08-03       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.